BDX

Becton, Dickinson and Company

Healthcare
144.43 -0.90 -0.62% Market Closed
2026-06-02 • USD

Key Metrics

Market Cap 39.80B
EV —
Shares Out 275.54M
Revenue (ttm) 22.16B
Net Income 1.14B
Beta —
P/E 35.62
Forward P/E —
EPS (ttm) $3.94
P/S 1.83
P/B 1.68
P/FCF —
P/C —
EV/Sales —
EV/EBITDA —
ROA 2.15%
ROE 4.59%
ROIC 4.99%
Gross Margin —
Oper. Margin 10.78%
Profit Margin 5.14%
Debt/Eq 0.72
LT Debt/Eq 37.86%
Quick Ratio —
Current Ratio 0.94
Book/sh 85.99
Cash/sh 2.9
Div Yield 2.89%
Div TTM $4.17
Payout Ratio 105.84%
SMA20 -1.24%
SMA50 -4.41%
SMA200 -6.48%
Volume 2,693,516
Avg Volume 3.01M
Rel Volume —
Perf Week -1.83%
Perf Month 0.18%
Perf Quarter -15.01%
Perf Half Y -25.54%
Perf YTD -5.33%
Perf Year -15.55%
Perf 3Y -43.14%
Perf 5Y -38.44%

Factor Lens

Seasonal Performance

Dividends

Per-share amounts adjusted for stock splits.

Last Dividend $1.0300
TTM Yield 2.89%
TTM Amount $4.17
Payout Ratio 105.84%
3-Yr Growth (CAGR) 6.13%
5-Yr Growth (CAGR) 5.65%

Last 12 Payouts

Period Ex-Date Amount / Share
Q4 2025 ~2026-04-01 $1.0300
Q2 2026 ~2026-03-31 $1.0500
Q1 2025 ~2025-12-31 $1.0500
Q3 2025 ~2025-06-30 $1.0400
Q4 2024 ~2025-04-01 $0.8600
Q2 2025 ~2025-03-31 $1.0400
Q1 2024 ~2024-12-31 $1.0400
Q3 2024 ~2024-06-30 $0.9500
Q2 2024 ~2024-03-31 $0.9500
Q4 2023 ~2024-03-31 $0.8700
Q1 2023 ~2023-12-31 $0.9500
Q3 2023 ~2023-06-30 $0.9100

Financial Trends

Revenue & Net Income

Earnings Per Share

Margins

Cash Flow

Company Overview

Becton, Dickinson and Company is a global innovator in medical technology, serving the healthcare industry across 190+ countries. BD manufactures and sells over 34 billion medical devices annually, supported by over 1.2 billion in annual research and development investment and 36,000+ active patents across four global enterprise R&D centers of excellence. The company operates through three primary segments: Medical (medication delivery, medication management, pharmaceutical systems, advanced patient monitoring, and urology/critical care solutions), Life Sciences (specimen management, diagnostic solutions, and biosciences), and Interventional (surgery, peripheral intervention, and urology/critical care products). BD is executing a strategic transformation to become a pure-play medical technology company through the planned combination of its Biosciences and Diagnostic Solutions businesses with Waters Corporation. The company achieved FY2025 revenues of $21.8 billion, with a consumables revenue profile exceeding 90% of total revenues in its future Medical segment, demonstrating a strong recurring revenue base.

Name
Becton, Dickinson and Company
Industry
Medical Devices
CEO
Thomas E. Polen · Chairman, Chief Executive Officer and President
Employees
74,500 as of 2025-09-30
IPO Date
2017-11-28
Phone
2018476800
Address
1 Becton Drive, Franklin Lakes, NJ 07417-1880
Website
www.bd.com

Key Executives

Name Title FY Pay
Bertram L. Scott Director —
R. Andrew Eckert Director —
Michael Garrison Chief Operating Officer —
Christopher DelOrefice Chief Financial Officer —
Thomas E. Polen Chairman, Chief Executive Officer and President —

Latest News